文章提出了一种新的基于MFS法(Method of Fundamental Solutions,即基本解法)的求解船舶势流问题的无网格数值方法。该方法采用势流控制方程的基本解表达流场中的速度势,可以得到任意阶连续的速度势导数;另外,通过引入流场虚边界的概念...文章提出了一种新的基于MFS法(Method of Fundamental Solutions,即基本解法)的求解船舶势流问题的无网格数值方法。该方法采用势流控制方程的基本解表达流场中的速度势,可以得到任意阶连续的速度势导数;另外,通过引入流场虚边界的概念避免了传统边界元方法中存在奇点的问题。相比传统的边界元方法,MFS法具有无奇性、不依赖网格、不涉及数值积分、数学原理简单和算法易于编程实现的优势。文中对于MFS法在求解浅水二维剖面水动力系数中的应用进行了探索,提出了一套实用的数值算法,并进一步结合频域切片法计算了Wigley船体的垂荡和纵摇响应,通过和频域面元法及试验结果的对比验证了方法的正确性和实用性;最后应用开发的程序分析了不同水深和航速对于耐波性的影响。该研究开创性地将MFS方法应用到了船舶水动力研究领域,为之后更深入广泛地应用这一特性优良的数值方法提供了有益的参考。展开更多
There is an urgent need for developing a procedure for biomarker standardization and relative quantificationin clinical laboratories. Measuring the expression levels of cell antigens is critical for the diagnosis of m...There is an urgent need for developing a procedure for biomarker standardization and relative quantificationin clinical laboratories. Measuring the expression levels of cell antigens is critical for the diagnosis of many diseases, e.g. leukemia, lymphoma and immunodeficiency diseases. One of the most significant challenges in flow cytometry is obtaining inter-laboratory and intra-laboratory consistent and reproducible results across multiple cytometer platforms and locations longitudinally over time. To obtain measurement consistency, the target flow cytometer voltages should be optimized to segregate the negative population from the electronic noise, and to keep the brightest positive population within the dynamic range of each detector. Then target values should be determined and transferred to selected cytometers. In this study, we optimized a procedure for instrument standardization across three different flow cytometer platforms from the same vendor and in two different locations. The biomarker quantification was implemented on standardized instruments using CD4 expression on T lymphocytes with a known amount of antibody bound per cell as a quantification standard. Our results on blood cell subset typing and CD19 quantification demonstrated that consistent and reliable results could be accomplished between instruments using the developed procedure. Quantitating the expression levels of certain cell biomarkers relative to a known reference marker before, during, and after therapy would provide important information for monitoring antibody-based therapy and could be potentially used to adjust dosing. Presently, we are implementing this protocol to quantify critical disease biomarkers, and making necessary modifications to the procedure to include instruments from different instrument manufacturers.展开更多
文摘文章提出了一种新的基于MFS法(Method of Fundamental Solutions,即基本解法)的求解船舶势流问题的无网格数值方法。该方法采用势流控制方程的基本解表达流场中的速度势,可以得到任意阶连续的速度势导数;另外,通过引入流场虚边界的概念避免了传统边界元方法中存在奇点的问题。相比传统的边界元方法,MFS法具有无奇性、不依赖网格、不涉及数值积分、数学原理简单和算法易于编程实现的优势。文中对于MFS法在求解浅水二维剖面水动力系数中的应用进行了探索,提出了一套实用的数值算法,并进一步结合频域切片法计算了Wigley船体的垂荡和纵摇响应,通过和频域面元法及试验结果的对比验证了方法的正确性和实用性;最后应用开发的程序分析了不同水深和航速对于耐波性的影响。该研究开创性地将MFS方法应用到了船舶水动力研究领域,为之后更深入广泛地应用这一特性优良的数值方法提供了有益的参考。
文摘There is an urgent need for developing a procedure for biomarker standardization and relative quantificationin clinical laboratories. Measuring the expression levels of cell antigens is critical for the diagnosis of many diseases, e.g. leukemia, lymphoma and immunodeficiency diseases. One of the most significant challenges in flow cytometry is obtaining inter-laboratory and intra-laboratory consistent and reproducible results across multiple cytometer platforms and locations longitudinally over time. To obtain measurement consistency, the target flow cytometer voltages should be optimized to segregate the negative population from the electronic noise, and to keep the brightest positive population within the dynamic range of each detector. Then target values should be determined and transferred to selected cytometers. In this study, we optimized a procedure for instrument standardization across three different flow cytometer platforms from the same vendor and in two different locations. The biomarker quantification was implemented on standardized instruments using CD4 expression on T lymphocytes with a known amount of antibody bound per cell as a quantification standard. Our results on blood cell subset typing and CD19 quantification demonstrated that consistent and reliable results could be accomplished between instruments using the developed procedure. Quantitating the expression levels of certain cell biomarkers relative to a known reference marker before, during, and after therapy would provide important information for monitoring antibody-based therapy and could be potentially used to adjust dosing. Presently, we are implementing this protocol to quantify critical disease biomarkers, and making necessary modifications to the procedure to include instruments from different instrument manufacturers.
